Los Angeles Capital Management LLC Buys 100 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Los Angeles Capital Management LLC grew its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,394 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the period. Los Angeles Capital Management LLC’s holdings in Mesa Laboratories were worth $448,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of MLAB. FMR LLC lifted its holdings in Mesa Laboratories by 34.1% in the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 100 shares during the period. Quantbot Technologies LP bought a new position in shares of Mesa Laboratories in the 3rd quarter worth approximately $70,000. Amalgamated Bank lifted its stake in shares of Mesa Laboratories by 6.5% in the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock valued at $206,000 after purchasing an additional 97 shares during the period. Captrust Financial Advisors bought a new stake in shares of Mesa Laboratories during the third quarter valued at approximately $207,000. Finally, Berry Wealth Group LP grew its stake in Mesa Laboratories by 5.3% in the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock worth $219,000 after purchasing an additional 83 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Stock Performance

Shares of MLAB opened at $135.44 on Tuesday. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $155.12. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. The stock has a market cap of $735.98 million, a P/E ratio of -2.93 and a beta of 0.83. The business’s 50 day moving average price is $139.89 and its 200-day moving average price is $129.46.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 EPS for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. Equities research analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.47%. The ex-dividend date of this dividend is Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is -1.38%.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.